DCOYDecoy Therapeutics Inc.
- Market cap
- $2.31M
- as of 2026-10-23
- Latest close
- $0.97
- as of 2026-10-23
- Sector
- Healthcare
- as of 2026-10-24
- Industry
- Biotechnology
- as of 2026-10-24
Cluster
No cluster in the last 90 days under the default rule (14d · ≥2 insiders · all roles).
Form 4 historysince 2024-02-22
| Insider | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Lieber Jonathan I | Aug 31 | Sep 2 | A | 2,000 | $0.00 | $0 | 2,002 | No | Form 4 |
| Pierce Frederick IIChief Executive Officer | Aug 31 | Sep 2 | A | 33,455 | $0.00 | $0 | 34,844 | No | Form 4 |
| Hanish Arnold C | Aug 31 | Sep 2 | A | 3,000 | $0.00 | $0 | 3,418 | No | Form 4 |
| Rosenblum Mark JChief Financial Officer | Aug 31 | Sep 2 | A | 9,682 | $0.00 | $0 | 11,363 | No | Form 4 |
| Lammers Paul | Aug 31 | Sep 2 | A | 2,000 | $0.00 | $0 | 2,001 | No | Form 4 |
| McVicar William K. | Aug 31 | Sep 2 | A | 3,000 | $0.00 | $0 | 3,002 | No | Form 4 |
| Burleson Tess | Aug 31 | Sep 2 | A | 2,000 | $0.00 | $0 | 2,002 | No | Form 4 |
| Hibner Barbara LouiseChief Scientific Officer | Aug 31 | Sep 2 | A | 4,216 | $0.00 | $0 | 4,216 | No | Form 4 |
| Marschel Peter KlausChief Business Officer | Aug 31 | Sep 2 | A | 3,900 | $0.00 | $0 | 3,900 | No | Form 4 |
| Gauthier Patricia G. | Aug 31 | Sep 2 | A | 2,000 | $0.00 | $0 | 2,000 | No | Form 4 |
| Hanish Arnold C | Dec 30, 2025 | Jan 2 | S | 15 | $0.64 | Sale −$10 | 5,000 | No | Form 4 |
| Hanish Arnold C | Dec 30, 2025 | Jan 2 | S | 12 | $0.64 | Sale −$8 | not reported | No | Form 4 |
| Hanish Arnold C | Nov 20, 2025 | Nov 24, 2025 | P | 5,000 | $0.75 | Purchase +$3,750 | 5,015 | No | Form 4 |
| Rosenblum Mark JExec VP Finance, CFO | Nov 20, 2025 | Nov 20, 2025 | P | 20,000 | $0.80 | Purchase +$16,000 | 20,177 | No | Form 4 |
| Arthur David J.Chief Executive Officer | Apr 11, 2024 | Apr 12, 2024 | A · derivative | 20,500 | $0.51 | $10,455 | 20,500 | No | Form 4 |
| Hanish Arnold C | Feb 20, 2024 | Feb 22, 2024 | A · derivative | 20,500 | $0.57 | $11,685 | 20,500 | No | Form 4 |
| Burleson Tess | Feb 20, 2024 | Feb 22, 2024 | A · derivative | 20,500 | $0.57 | $11,685 | 20,500 | No | Form 4 |
| Lammers Paul | Feb 20, 2024 | Feb 22, 2024 | A · derivative | 20,500 | $0.57 | $11,685 | 20,500 | No | Form 4 |
| Lieber Jonathan I | Feb 20, 2024 | Feb 22, 2024 | A · derivative | 20,500 | $0.57 | $11,685 | 20,500 | No | Form 4 |
| McCreedy Bruce J Jr. | Feb 20, 2024 | Feb 22, 2024 | A · derivative | 20,500 | $0.57 | $11,685 | 20,500 | No | Form 4 |
| McVicar William K. | Feb 20, 2024 | Feb 22, 2024 | A · derivative | 20,500 | $0.57 | $11,685 | 20,500 | No | Form 4 |
| Rosenblum Mark JExec VP Finance, CFO | Feb 20, 2024 | Feb 22, 2024 | A · derivative | 22,500 | $0.57 | $12,825 | 22,500 | No | Form 4 |